Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ponatinib
Drug ID BADD_D01799
Description Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Indications and Usage Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
Marketing Status Prescription
ATC Code L01EA05
DrugBank ID DB08901
KEGG ID D09950
MeSH ID C545373
PubChem ID 24826799
TTD Drug ID D0H0EQ
NDC Product Code Not Available
Synonyms ponatinib | 3-(2-(imidazo(1,2-b)pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-y-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide | ponatinib hydrochloride | AP24534 | AP-24534 | AP 24534 | Iclusig
Chemical Information
Molecular Formula C29H27F3N6O
CAS Registry Number 943319-70-8
SMILES CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dry eye06.08.02.001--
Dry mouth07.06.01.0020.000799%
Dry skin23.03.03.0010.005595%
Dysmetria17.02.02.0050.000533%Not Available
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dysphonia22.02.05.005; 19.19.03.002; 17.02.08.0040.000799%
Dyspnoea22.02.01.004; 02.01.03.0020.005595%
Ecchymosis01.01.03.001; 24.07.06.002; 23.06.01.001--Not Available
Eczema23.03.04.0060.000799%
Electrocardiogram QT prolonged13.14.05.004--
Embolism venous24.01.01.003--Not Available
Encephalopathy17.13.02.0010.000533%
Eosinophil count increased13.01.06.0040.000533%Not Available
Epistaxis24.07.01.005; 22.04.03.001--
Epstein-Barr virus infection11.05.10.0040.000533%
Erythema23.03.06.0010.001865%Not Available
Eye disorder06.08.03.001--Not Available
Eye haemorrhage06.07.02.001; 24.07.05.0020.000533%Not Available
Eyelid oedema06.04.04.004; 23.04.01.003; 10.01.05.001--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.0030.000533%
Fatigue08.01.01.0020.011456%
Febrile neutropenia08.05.02.004; 01.02.03.0020.002398%
Feeling abnormal08.01.09.014--Not Available
Fluid overload14.05.06.001; 02.05.04.0040.000533%Not Available
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Folliculitis23.09.04.007; 11.01.12.018--
Fungal infection11.03.05.0010.000799%Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 14 Pages